Dataset related to article "Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO)"

Abstract INTRODUCTION: The prognosis of glioma is dismal, and almost all patients relapsed. At recurrence time, several treatment options are considered, but to date there is no a standard of care. The Neurooncology Study Group of the Italian Association of Radiation Oncology (AIRO) collected clinical data regarding a large series of recurrent glioma patients who underwent re-irradiation (re-RT) in Italy. METHODS: Data regarding 300 recurrent glioma patients treated from May 2002 to November 2017, were analyzed. All patients underwent re-RT. Surgical resection, followed by re-RT with concomitant and adjuvant chemotherapy was performed. Clinical outcome was evaluated by neurological examination and brain MRI performed, 1 month after radiation therapy and then every 3 months. RESULTS: Re-irradiation was performed at a median interval time (IT) of 16 months from the first RT. Surgical resection before re-RT was performed in 19% of patients, concomitant temozolomide (TMZ) in 16.3%, and maintenance chemotherapy in 29%. Total doses ranged from 9 Gy to 52.5 Gy, with a median biological effective dose of 43 Gy. The median, 1, 2 year OS were 9.7 months, 41% and 17.7%. Low grade glioma histology (p ≪ 0.01), IT &gt; 12 months (p = 0.001), KPS &gt; 70 (p = 0.004), younger age (p = 0.001), high total doses delivered (p = 0.04), and combined treatment performed (p = 0.0008) were recorded as conditioning survival. CONCLUSION: our data underline re-RT as a safe and feasible treatment with limited rate of toxicity, and a combined ones as a better option for selected patients. The identification of a BED threshold able to obtain a greater benefit on OS, can help in designing future prospective studies.摘要：胶质瘤的预后极差，几乎所有患者均会出现肿瘤复发。复发阶段临床可考量多种治疗方案，但截至目前尚无标准治疗方案。意大利放射肿瘤学协会（Italian Association of Radiation Oncology, AIRO）神经肿瘤研究组收集了意大利境内接受再放疗（re-RT）的大样本复发胶质瘤患者的临床数据。方法：本研究分析了2002年5月至2017年11月间收治的300例复发胶质瘤患者的临床资料，所有患者均接受再放疗；部分患者在再放疗前接受手术切除，随后行同步联合辅助化疗。临床疗效通过放疗结束1个月后的神经系统检查及脑部MRI扫描进行评估，此后每3个月复查一次。结果：首次放疗至再放疗的中位间隔时间为16个月。19%的患者在再放疗前接受了手术切除，16.3%的患者接受了同步替莫唑胺（TMZ）治疗，29%的患者接受了维持化疗。总照射剂量范围为9 Gy至52.5 Gy，中位生物学有效剂量为43 Gy。患者的中位总生存期（overall survival, OS）为9.7个月，1年总生存率为41%，2年总生存率为17.7%。多因素分析显示，低级别胶质瘤组织学类型（p < 0.01）、间隔时间＞12个月（p = 0.001）、Karnofsky功能状态评分（KPS）＞70（p = 0.004）、年龄较轻（p = 0.001）、较高的总照射剂量（p = 0.04）以及联合治疗方案（p = 0.0008）为影响患者生存预后的独立有利因素。结论：本研究数据证实，再放疗是一种安全可行的治疗手段，毒性反应发生率有限，而联合治疗方案可为经过筛选的患者提供更优的治疗选择。明确可对总生存期带来显著获益的生物学有效剂量阈值，将有助于未来前瞻性研究的设计。